{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:48:49Z","timestamp":1790218129577,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T00:00:00Z","timestamp":1699315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T00:00:00Z","timestamp":1699315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1038\/s41391-023-00751-6","type":"journal-article","created":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T13:02:06Z","timestamp":1699362126000},"page":"334-338","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Early PSA decline after starting second-generation hormone therapy in the post-docetaxel setting predicts cancer-specific survival in metastatic castrate-resistant prostate cancer"],"prefix":"10.1038","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0054-2710","authenticated-orcid":false,"given":"Mohamed E.","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5583-9749","authenticated-orcid":false,"given":"Matthew S.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2002-685X","authenticated-orcid":false,"given":"Ahmed M.","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidhu B.","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Gopalakrishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raevti","family":"Bole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimki","family":"Haloi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Tuba","family":"Kendi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Bold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0206-3895","authenticated-orcid":false,"given":"Alan H.","family":"Bryce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Jeffrey","family":"Karnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene D.","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"Childs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack R.","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,7]]},"reference":[{"key":"751_CR1","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1080\/14656566.2018.1527312","volume":"19","author":"G Baciarello","year":"2018","unstructured":"Baciarello G, Gizzi M, Fizazi K. Advancing therapies in metastatic castration-resistant prostate cancer. Expert Opin Pharmacother. 2018;19:1797\u2013804.","journal-title":"Expert Opin Pharmacother"},{"key":"751_CR2","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/bco2.116","volume":"3","author":"Y Khoshkar","year":"2022","unstructured":"Khoshkar Y, Westerberg M, Adolfsson J, Bill-Axelson A, Olsson H, Eklund M, et al. Mortality in men with castration-resistant prostate cancer-A long-term follow-up of a population-based real-world cohort. BJUI Compass. 2022;3:173\u201383.","journal-title":"BJUI Compass"},{"key":"751_CR3","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/nrc801","volume":"2","author":"SR Denmeade","year":"2002","unstructured":"Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nat Rev Cancer. 2002;2:389\u201396.","journal-title":"Nat Rev Cancer"},{"key":"751_CR4","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1053\/j.seminoncol.2018.10.001","volume":"45","author":"G Ingrosso","year":"2018","unstructured":"Ingrosso G, Detti B, Scartoni D, Lancia A, Giacomelli I, Baki M, et al. Current therapeutic options in metastatic castration-resistant prostate cancer. Semin Oncol. 2018;45:303\u201315.","journal-title":"Semin Oncol"},{"key":"751_CR5","unstructured":"FDA approves pluvicto\/locametz for metastatic castration-resistant prostate cancer. J Nucl Med. 2022;63:13N."},{"key":"751_CR6","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","volume":"387","author":"ND James","year":"2016","unstructured":"James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387:1163\u201377.","journal-title":"Lancet."},{"key":"751_CR7","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737\u201346.","journal-title":"N Engl J Med"},{"key":"751_CR8","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S1470-2045(15)00489-1","volume":"17","author":"CL Vale","year":"2016","unstructured":"Vale CL, Burdett S, Rydzewska LHM, Albiges L, Clarke NW, Fisher D, et al. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol. 2016;17:243\u201356.","journal-title":"Lancet Oncol"},{"key":"751_CR9","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/pros.23954","volume":"80","author":"JR Andrews","year":"2020","unstructured":"Andrews JR, Ahmed ME, Karnes RJ, Kwon E, Bryce AH. Systemic treatment for metastatic castrate resistant prostate cancer: does seqence matter? Prostate. 2020;80:399\u2013406.","journal-title":"Prostate."},{"key":"751_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-10-126","volume":"10","author":"AJ O\u2019Neill","year":"2011","unstructured":"O\u2019Neill AJ, Prencipe M, Dowling C, Fan Y, Mulrane L, Gallagher WM, et al. Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. Mol Cancer. 2011;10:126.","journal-title":"Mol Cancer"},{"key":"751_CR11","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.eururo.2016.07.032","volume":"71","author":"TM Beer","year":"2017","unstructured":"Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study. Eur Urol. 2017;71:151\u20134.","journal-title":"Eur Urol"},{"key":"751_CR12","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187\u201397.","journal-title":"N Engl J Med"},{"key":"751_CR13","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995\u20132005.","journal-title":"N Engl J Med"},{"key":"751_CR14","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/pcan.2016.71","volume":"20","author":"AH Bryce","year":"2017","unstructured":"Bryce AH, Alumkal JJ, Armstrong A, Higano CS, Iversen P, Sternberg CN, et al. Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL. Prostate Cancer Prostatic Dis. 2017;20:221\u20137.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"751_CR15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3389\/fphar.2016.00123","volume":"7","author":"G Facchini","year":"2016","unstructured":"Facchini G, Caffo O, Ortega C, D\u2019Aniello C, Di Napoli M, Cecere SC, et al. Very early PSA response to abiraterone in mCRPC patients: a novel prognostic factor predicting overall survival. Front Pharm. 2016;7:123.","journal-title":"Front Pharm"},{"key":"751_CR16","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.eururo.2016.02.055","volume":"70","author":"P Rescigno","year":"2016","unstructured":"Rescigno P, Lorente D, Bianchini D, Ferraldeschi R, Kolinsky MP, Sideris S, et al. Prostate-specific antigen decline after 4 weeks of treatment with abiraterone acetate and overall survival in patients with metastatic castration-resistant prostate cancer. Eur Urol. 2016;70:724\u201331.","journal-title":"Eur Urol"},{"key":"751_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5729-7","volume":"19","author":"JP Schiff","year":"2019","unstructured":"Schiff JP, Cotogno P, Feibus A, Steinwald P, Ledet E, Lewis B, et al. Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer. BMC Cancer. 2019;19:524.","journal-title":"BMC Cancer"},{"key":"751_CR18","doi-asserted-by":"publisher","first-page":"12315","DOI":"10.1073\/pnas.1922207117","volume":"117","author":"JJ Alumkal","year":"2020","unstructured":"Alumkal JJ, Sun D, Lu E, Beer TM, Thomas GV, Latour E, et al. Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance. Proc Natl Acad Sci USA. 2020;117:12315\u201323.","journal-title":"Proc Natl Acad Sci USA"},{"key":"751_CR19","doi-asserted-by":"publisher","first-page":"40085","DOI":"10.18632\/oncotarget.9485","volume":"7","author":"E Verzoni","year":"2016","unstructured":"Verzoni E, De Giorgi U, Derosa L, Caffo O, Boccardo F, Facchini G, et al. Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study. Oncotarget. 2016;7:40085\u201394.","journal-title":"Oncotarget."},{"key":"751_CR20","doi-asserted-by":"publisher","first-page":"3901","DOI":"10.21873\/anticanres.13541","volume":"39","author":"LW Chang","year":"2019","unstructured":"Chang LW, Hung SC, Wang SS, Li JR, Yang CK, Chen CS, et al. Abiraterone acetate and enzalutamide: similar efficacy in treating post docetaxel metastatic castration-resistant prostate cancer: single center experience. Anticancer Res. 2019;39:3901\u20138.","journal-title":"Anticancer Res"},{"key":"751_CR21","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.euo.2018.11.005","volume":"2","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Lin P, Higano CS, Iversen P, Sternberg CN, Tombal B, et al. Prognostic association of prostate-specific antigen decline with clinical outcomes in men with metastatic castration-resistant prostate cancer treated with enzalutamide in a randomized clinical trial. Eur Urol Oncol. 2019;2:677\u201384.","journal-title":"Eur Urol Oncol"},{"key":"751_CR22","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1002\/pros.24413","volume":"82","author":"J Alamiri","year":"2022","unstructured":"Alamiri J, Britton CJ, Ahmed ME, Andrews JR, Higa JL, Dundar A, et al. Radiographic paradoxical response in metastatic castrate-resistant prostate cancer (mCRPC) managed with new generation anti-androgens: a retrospective analysis. Prostate. 2022;82:1483\u201390.","journal-title":"Prostate."},{"key":"751_CR23","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.clgc.2016.07.026","volume":"15","author":"Y Ueda","year":"2017","unstructured":"Ueda Y, Matsubara N, Tabata KI, Satoh T, Kamiya N, Suzuki H, et al. Prostate-specific antigen flare phenomenon induced by abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2017;15:320\u20135.","journal-title":"Clin Genitourin Cancer"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-023-00751-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-023-00751-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-023-00751-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T07:04:52Z","timestamp":1715756692000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-023-00751-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,7]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["751"],"URL":"https:\/\/doi.org\/10.1038\/s41391-023-00751-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2819133\/v1","asserted-by":"object"}]},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,7]]},"assertion":[{"value":"14 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}